The CDC’s most recent Health, United States report, released this April, reveals the extent to which racial and ethnic disparities in the U.S. affect cardiovascular care and rates of heart disease in the country.

A study of nearly 4,000 patients with coronary artery disease (CAD) has linked blood pressure variability (BPV) between clinic visits to significantly greater progression of coronary atheroma and major adverse events, suggesting BP stability might be an important factor in CAD care.

The cardiology division at Columbia University’s Vagelos College of Physicians and Surgeons received a donation of $32.5 million this month—a gift the program’s leaders say will go toward patient care, research and education.

Pharmacy closures across the U.S. are driving significant declines in medication adherence among Americans, a recent study has found, especially those who are older and live in neighborhoods with low accessibility.

A cardiologist at St. Joseph’s Hospital in Syracuse, N.Y., is one of 60 that’s been charged in an illegal prescription opioid scandal that spans the U.S.

The American Academy of Pediatrics’ (AAP) updated blood pressure guidelines classify more kids in higher BP categories and can more accurately predict which children are prone to heart disease later in life, an extensive analysis of the Bogalusa Heart Study has found.

Torrent Pharmaceuticals Limited has expanded its recent recall of blood pressure-regulating losartan tablets to include an additional 104 lots of the drugs, the company announced April 18.

Eating a late dinner and skipping breakfast could raise heart patients’ risk of a repeat MI or death by up to fivefold, according to research published in the European Journal of Preventive Cardiology April 17.

Two studies published April 18 in the journal Cell have shined new light on the role genetics can play in developing obesity—or protecting against it.

The 71-year-old Framingham Heart Study has received $38 million from the National Heart, Lung, and Blood Institute to fund a new six-year study into the biology of aging.

The first study to test an experimental antiplatelet compound in humans found the therapy inhibited clot formation without increasing bleeding, suggesting it could avoid that dangerous side effect of other clot-preventing drugs.

The popular diabetes drug metformin reversed left ventricular hypertrophy (LVH) in a randomized trial of patients with coronary artery disease but without diabetes, suggesting a potential new use for the medication.